Resources

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

In a shifting global landscape, we break down how the UK's new Trade and National Security strategies aim to future-proof our biotech sector.

We're pleased to announce the appointment of Livija Deban, Chief Scientific Officer at Prokarium, as Chair of its Engineering Biology Advisory Committee (EBAC).

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, shares insights from the BIA's first-of-its-kind funding and investment analysis into UK Deep Biotech.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

This week I highlight innovation across the sector and call on pension funds to be mandated to support our industry.

The BioIndustry Association (BIA) has today published a report highlighting the rapid growth of the UK’s Deep Biotech sector.

In a world of uncertainty, Britain’s biotech future looks strong.

This week saw the publication of Engineering Biology Aspirations, the final output of Angela McLean’s Year of Engineering Biology. The report sets out an ambitious, forward-looking vision for the field, exploring how engineering biology could shape the future of everything from food and fashion to fuel and health.

The UK pavilion at SynBioBeta 2025 will unite leading UK engineering biology companies and ecosystem partners to highlight the UK’s world-class strengths in engineering biology.

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.